4 completed, 2 recruiting. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Recruiting 2 |
| Phase 2 | 5 | Completed 4, Recruiting 1 |
Follow Samuraciclib: new trials by email Literature Review of Samuraciclib trials Research Report on Samuraciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy - Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | University of Washington | 15 | 2026-10-15 | 2026-09-21 |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) vepdegestrant, Samuraciclib - Breast Cancer | Phase 1 / Phase 2 | Completed | Pfizer | 11 | 2024-01-10 | 2026-10-02 |
| A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants Samuraciclib, Fulvestrant - Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 2 | Completed | Carrick Therapeutics Limited | 60 | 2023-11-16 | 2025-12-26 |
| A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer Samuraciclib, Elacestrant Dihydrochloride - Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 1 / Phase 2 | Completed | Carrick Therapeutics Limited | 49 | 2023-10-09 | 2026-03-23 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer Giredestrant, Abemaciclib, Ipatasertib - Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 316 | 2021-06-22 | 2026-10-06 |
| Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies CT7001, Fulvestrant - Advanced Solid Malignancies | Phase 1 / Phase 2 | Completed | Carrick Therapeutics Limited | 124 | 2017-11-14 | 2026-06-23 |
Breast Neoplasms (3) · Neoplasm Metastasis (1) · Neoplasms (1)
Carrick Therapeutics Limited (3) · Hoffmann-La Roche (1) · Pfizer (1) · University of Washington (1)
United States (6) · Spain (3) · France (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Hungary (1) · Israel (1) · Italy (1) · Mexico (1) · South Korea (1) · Turkey (Türkiye) (1)
Andrew Coveler, MD (1) · Matthew Krebs, MBChB PhD (1)
2023 (4), 2017 (1)